According to filings with the U.S. Securities and Exchange Commission, NephroDI Therapeutics is raising up to $3,999,999.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Rachael Hagan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NephroDI Therapeutics
NephroDI Therapeutics is a pre-clinical development stage biopharmaceutical company that focuses on concentration disorders of the kidney. The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus in children, a pediatric orphan indication. Nephrogenic Diabetes Insipidus (NDI) is a disease where patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin. Congenital NDI in the pediatric population results primarily from mutations in the type 2 vasopressin receptor, which is located on the X chromosome. Congenital NDI has a profound impact on children. Since these children can produce up to 20 L of urine per day, They must drink 20 L (80 8oz glasses) of water per day to avoid dehydration. Children who suffer multiple episodes of severe dehydration often end up with mental retardation.

To learn more about NephroDI Therapeutics, visit http://nephrodi.com/
Company Linkedin Page: https://www.linkedin.com/company/nephrodi-therapeutics-inc/

Contact:
Rachael Hagan, President and Chief Executive Officer
206-696-0546
https://www.linkedin.com/in/rahagan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.